论文部分内容阅读
本文报道,口服替马沙星对8株临床常见致病菌经腹腔感染小鼠的体内保护实验。结果显示:替马沙星对金黄色葡萄球菌、大肠杆菌、肺炎杆菌和绿脓杆菌各两株感染小鼠均具良好体内保护作用。其中对金黄色葡萄球菌杆染的保护作用明显优于对照药环丙沙星,两株菌感染的ED_(50)分别是3.10mg/kg和4.33mg/kg,比环丙沙星强三倍;对大肠杆菌感染的保护作用比环丙沙星差2～3倍;对各一株肺炎杆菌和绿脓杆菌感染的保护作用和环丙沙星相似,而对另外一株肺炎杆菌和一株绿脓杆菌感染的保护作用比环丙沙星差。 实经结果表明;替马沙星具有良好体内抗菌作用。
This article reports, oral tebufenoxacin eight in vivo clinical pathogenic bacteria infected mice by intraperitoneal in vivo protection. The results showed that: Tirimafloxacin against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa two infected mice have good in vivo protective effect. Among them, the protective effect of Staphylococcus aureus rod dyeing was significantly better than the control drug ciprofloxacin, ED_ (50) of the two strains were 3.10mg / kg and 4.33mg / kg respectively, three times stronger than ciprofloxacin ; Protective effect of Escherichia coli infection than ciprofloxacin 2 to 3 times; for each of a protective effect of Klebsiella pneumoniae and Pseudomonas aeruginosa infection and ciprofloxacin similar to another strain of Klebsiella pneumoniae and a Pseudomonas aeruginosa infections are less protective than ciprofloxacin. The results show that: for the good effect of in vivo antibacterial effect.